infinity medical receivables fund, lp

Private & Confidential

INFINITY MEDICAL RECEIVABLES FUND, LP

Private & Confidential 2

Tecumseh’s investment philosophy and processes are based upon a nuanced method that relies heavily on the underwriting process utilized by the Sub-Adviser(s), and may have varying results depending on numerous factors. A number of important risks should be considered prior to making an investment. Refer to the Fund’s offering document for a more thorough discussion of relevant risk factors. While each of the

underwriting processes seek to eliminate all risks associated with investments in the strategy. Any projections of the Fund’s performance or potential performance are entirely speculative and no representations or warranties whatsoever are made by Tecumseh or any other person or entity as to the future profitability of an investment account or the results of making an investment based on this or any other method.


The TECUMSEH Infinity Medical Receivables Fund, LP provides investors with exposure to an asset class that is non-correlated to broad equity and fixed income returns, at a low minimum investment size.

The TECUMSEH – Infinity Medical Receivables Fund, LP is sub-Advised by Infinity Capital management which has historically generated superior risk-adjusted returns.

The strategy of the TECUMSEH – Infinity Medical Receivables Fund, LP is to acquire an interest in medical receivables relating to services rendered to plaintiffs in connection to personal injury cases where a lawyer has been retained. The sub-Advisor analyzes individual cases and recommends for purchase only those receivables relating to claims with the highest likelihood of settling and being paid out by an insurance company.

THE STRATEGY


TECUMSEH - INFINITYInfinity Medical Receivables Fund, LP

INVESTMENT MANAGER TECUMSEH ALTERNATIVES, LLC

Sub-Advisor Infinity Capital Management

Management Fee 2% annually

Incentive Fee 20%

Dividend Distribution (Optional) 8% annually

Minimum Investment $100,000

Fund Termination Date November 30, 2023

Closing Schedule Monthly – last June 30, 2021

Next Closing Investment Cap $5,000,000

4


INVESTMENT STRATEGY FOR THE US HEALTH CARE SERVICE INDUSTRY

5

Personal Injury Medical Imaging Pain Management Pharmaceuticals


ABOUT INFINITY

6

Hospitals & Surgical Centers

Physical Therapy General Orthopedic

Spinal

Infinity was established in 1997 and is one of the pioneers in personal injury receivables.

Arthroscopic Pulmonary Ear, Nose & Throat Cosmetic/Facial

Infinity operates within an extensive network of specialist health care providers such as:


ABOUT INFINITY

7

Infinity was established in 1997 and is one of the pioneers in personal injury receivables.

Urology Anesthesiology Pain Management

Dentistry Neurology & Neurosurgery

Hand & Microvascular

Joint Replacement & Home Health

Care

Infinity operates within an extensive network of specialist health care providers such as:


MEDICAL CARE ON A LIENInfinity Health’s Target Receivables Opportunities

PHARMACEUTICALSPatients have out of pocket

costs or high co-pay

Attorney clients that have been in an accident suffer from injuries and

are in pain. Easy, fast and nationwide access to essential medications prescribed by a physician are a need to be

addressed in most Personal Injury cases and is a multi-billion-dollar opportunity. Infinity provides a

solution that is cost effective and fully automated through an easy to

manage web interface. The prescription is available to

attorney clients without co-pay or any other upfront costs and can be

paid at settlement of the case.

PERSONAL INJURYHigh costs and

operationally draining for attorneys

Medical treatments ranging from office visits to complex surgeries

fall into this category. Infinity has a long history of being one of the national leaders in underwriting

these cases with a loss rates of less than 2% compared to the national

average of over 10%.

MEDICAL IMAGINGEssential to establish

value of case

Medical imaging alone is a multi-billion-dollar market. Infinity

purchases from imaging providers, in bulk at a significant discount.

Imaging facilities sell their receivables to fund operations and

expansion. Infinity becomes a long-term partner to help with

those objectives. This high volume-based business, requiring

thousands of imaging procedures to be processed every month, can

only be done with a highly sophisticated IT system such as

what that Infinity has developed over many years.

PAIN MANAGEMENT

Essential to patient’s well being if surgery can be

avoided

Pain management procedures can sometimes help patients get

back to their lives without undergoing a risky surgery. The nationwide yearly receivable

volume is also in the multi-billion-dollar range. Pain management

procedures are similar to imaging. It is high volume and

requires sophisticated systems to track, manage and collect. The

price point is slightly higher than imaging.

8


MEDICAL CARE LIENS

Personal Injury Medical Imaging

Pain Management


MEDICAL CARE LIEN PROCESS

MEDICAL PROVIDER

TECUMSEH-INFINITY

FUND

Pays after services have been provided to Patient

Paid After settlement from Insurance Company

Provides Medical Services

Signs Lien Documents & Provides Case Information

ATTORNEY PATIENT

Signs Lien Documents

Manages Client’s Case

MEDICAL CARE ON A LIEN

1+2. Lawyer and Client are interested in lien funding services and have a solid case to back it, sign liens and provide case information to Tecumseh-Infinity Fund.

3. Medical Provider treats patient and invoices Tecumseh-Infinity Fund.

4. Tecumseh-Infinity Fund pays pre-negotiated, discounted rate to medical provider, or purchases existing aged receivables in batch.

5. Tecumseh-Infinity Fund receives insurance proceeds at settlement, based on retail cost of services provided.

5. 2. 2.

4.

3.

1.

10


BUSINESS PROCESSMain Steps to Process Health Care Lien

CASE INTAKE

The Tecumseh-Infinity Fund Intake Team

evaluates requests from Attorneys and/or

Medical Providers to accept medical treatment

lien

CASE MANAGEMENT

Approved Cases are entered into Case Manager Software System including all

relevant case information and expenses are

tracked and evaluated against insurance policy limits. Medical Providers

are being paid for services.

SETTLEMENT REVENUES

After Treatment the Tecumseh-Infinity Fund Managers follow up with the attorneys on

case status and settlements in order to

collect proceeds

11


PHARMACEUTICALS LIENNew Marketing Approach prescriptions Lien


SUMMARY

13

Medical Care Lien

Between accident and settlement • 20+ Years Experience in the Industry

• Existing Network of 100+ Medical Providers

• Existing Network of 1,000+ Attorneys

• Trained Personnel (about 20)

• Scaleable IT Systems

• Unique approaches for Medical Records Services and Pharmaceuticals on a Lien


OFFERING DETAILSTecumseh-Infinity Medical Receivables Fund offers investors a way to enter the emerging medical receivables market

14


Secured Receivables Medical receivables secured by underlying lawsuits sit in the fund and are owned by the investors.

Leverage The fund will not employ leverage.

Target Fund Size $25 Million. The General Partner has the right to accept commitments in excess of this amount.

Administration Third-party administration handling all transactions on behalf of clients and investors.

Quarterly Income Distribution 8% preferred, paid out quarterly.

Investment Structure Delaware LP (3c1).

Reinvestment PeriodCapital invested by the Fund in any Fund investment which is realized within 30 months of the initial closing and returned to the fund will be added back to the unfunded capital.


OFFERING DETAILSTecumseh-Infinity Medical Receivables Fund offers investors a way to enter the emerging medical receivables market

15


Investor Liquidity Principal and profits expected to be returned within 42 months, no redemptions.

Investment Return Objective High teens to mid 20‘s, net of all fees and expenses.

Minimum Investor Commitment $100k USD.

Drawdown Structure Generally, all capital commitments will be called immediately.

Incentive Allocation 20%.

Management Fee 2% of called commitments during the commitment period; 2% of invested capital after commitment period.

Investor/Sponsor Waterfall • First 100% principal returned to LPs• Preferred internal rate of return of 8% to LPs• Catch-up: 100% to the GP until the GP has received 20% of the preferred return• 80/20 profit split between LP/GP thereafter


TECUMSEH SERVICE PROVIDERS

TECUMSEH Alternatives works with top industry experts to provide an investor-friendly and transparent investor experience

16

GENERAL COUNSELADMINISTRATOR BANKING & TRUST AUDIT


Infinity Capital Management was established in 1997. It is a lien funding company with an extensive network of specialist health care providers, including hospitals and surgery centers. Its mission is to help patients receive healthcare and access as many medical options as possible by financing the cost of medical care. Attorneys use Infinity to assist in locating medical specialties that may be needed by their clients, as they do not have the time or resources to do so.

Utilizing this extensive network, Infinity will source attractive receivables for purchase by the Fund.

17

INFINITY CAPITAL MANAGEMENT – SUB ADVISOR TO TECUMSEH - INFINITY MEDICAL RECEIVABLES FUND, LP


ANNE PANTELASFOUNDER & PRESIDENT

Anne has a Bachelor of Economics from the University of Sydney, Australia and a Master’s in Commerce from the University of New South Wales, Australia. She is a registered CPA and a fellow of the Australian Society of Certified Practicing Accountants. Anne has over 19 years of experience in the investment and finance industry. Prior to coming to the United States, Ms. Pantelasserved as manager in the corporate banking group at the State Bank of South Australia. She was then an industrial analyst for Prudential Assurance Company Limited providing recommendations and direction for the firm’s multi-billion-dollar investment portfolio. She then joined senior management at the Royal Bank of Canada in Australia.

While serving as a manager at the National Mutual Royal Bank Limited, Ms. Pantelas was responsible for the sourcing and structuring of major financial transactions for corporate clients. On moving to Las Vegas in 1994, she began consulting and assisting many local businesses with financial matters. In 1997 Ms. Pantelas co-founded Infinity Capital Management, which underwrites hospital receivables, focusing on personal injury funding. Under her leadership Infinity has become a leader in the industry with a network of close to 200 attorneys and over 100 medical providers.


OLIVER HEMMERSVICE PRESIDENT OF OPERATIONS

Dr. Hemmers assumed the role of Vice President of Operations at Infinity Capital Management in 2014. In that position, he focuses on workflow optimization, database design and implementation, process optimization and control, reporting, business development as well as data management and data security. In 2002, Dr. Hemmers co-founded GPmicro, Inc. that specializes in automated, off-site (cloud) data backup, data protection, and data retrieval for small businesses with a focus on the health care industry. He also developed his first patent, which was on offsite data replication. More recently, Dr. Hemmers became the President of Skybot Challenge in January 2015, which is a 501(c)3 nonprofit corporation providing a regional STEM program for middle and high school students to learn about quadcopter (drones or UAVs) engineering and piloting through school competitions. Before venturing into private industry, Dr. Hemmers’ career spanned over 25-years focusing on research, academia and research management. Dr. Hemmers received a Dr. rer. nat. (rerum naturalium) in experimental atomic and molecular physics from the Institute for Radiation and Nuclear Physics at the Technical University in Berlin, Germany (1993) while working as research scientist at the Max-Planck Society in Berlin. In 2006 Dr. Hemmers became the Director of the Office of Strategic Energy Programs (OSEP) at UNLV,to foster renewable energy research at UNLV. In 2008, Dr. Hemmers became the Executive Director of the Harry Reid Center (HRC). Dr. Hemmers’ research interests include optimization of biodiesel/biofuel production processes, hydrogen fuel storage technologies, materials for solar power production, new materials under extreme conditions for energy research, physics of climate change, applications of soft x-ray spectroscopy using synchrotron radiation on gas-phase, solids and surfaces to probe electronic structures, correlations and processes, high-energy X-ray applications, material science such as the synthesis and characterization of glass-ceramic composites. As an academic, he prepared for approximately 200 presentations at national and international meetings, published over 100 research articles, wrote one book, and holds two patents. He is also a reviewer for the American Institute ofPhysics, the Institute of Physics, and national and international funding agencies.


THE MANAGEMENT TEAM


MICHAEL BELOTZMike has seventeen years of hedge fund portfolio management and research experience covering all investment sectors. This follows a long career on the sell side in both trading and marketing in the derivatives of equities and commodities. This includes three years as a floor trader in equity options on the American Stock Exchange where he traded a diverse book of derivatives on individual equities. Later he specialized in commodity derivatives as both a marketer and structurer for firms such as Chase, Societe Generale and Kidder Peabody. In these roles he devised derivative structures in crude oil, products and natural gas as well as put together financing packages for energy production and transportation projects. He also spent time as a risk management professional during the initial deregulation of the US electricity market for a major utility.

Currently, he is Head of US for DNA Partners where he is responsible for sourcing and due diligence of US based hedge funds. This follows his time as the Head of Research and Risk Management at Lanx Management, a Fund of Hedge Funds. Prior to that, he was Head of Portfolio Management in the US for the Fund of Hedge Funds Group at Credit Suisse where he ran $6 Billion in portfolios. Michael started out his hedge fund career at TAG Associates, a multi-client family office, as the portfolio manager for their relative value and diversified strategy fund of funds.

Mike has his MBA from The Wharton School and a BS in business from the University of California, Berkeley.


CHAD MEYERChad was most recently President and co-founder of HedgeACT, an investable platform of non-correlated alternative investments. Chad helped found the firm in 2013 and grew it to 11 hedge funds, more than $100 million in assets, and $1 million in recurring revenue at the time of his departure in May 2019.

Prior to HedgeACT, Chad was focused on the application of technology to the investment advisory industry. In 2000, he founded BridgePortfolio.com, which was an industry-leader in providing outsourced back-office services.

Utilizing proprietary technology, BridgePortfolio.com greatly improves the efficiency and transparency of hundreds of registered investment advisors, across several billion dollars in managed assets. Chad sold BridgePortfolio to a larger financial services company in Chicago in 2011.

Chad graduated Magna Cum Laude with a BA in Economics from Cornell University, where he played varsity tennis, and also holds a law degree from the University of Pennsylvania, and an MBA from the University of Chicago.

CONTACT INFORMATION

MICHAEL [email protected] Alternatives LLC New York, New York646.469.5612

CHAD [email protected] Alternatives LLC 5668 Morris Hunt DriveFort Mill, SC 29708312.543.2204


mailto:[email protected]

mailto:[email protected]


TECUMSEHInfinity Medical Receivables Fund Presentation Disclaimer

This presentation does not constitute an offer to purchase securities of Tecumseh-Infinity Medical Receivables Fund (the “Fund”) or of the Fund’s General Partner, Tecumseh Alternatives, LLC (the “General Partner” or “Tecumseh”), or any of the Fund’s partners or affiliates. Such an offer will only be made pursuant to the confidential offering document for the Fund. The information contained herein is confidential and is provided to you solely for informational purposes only. This information is not to be shared, distributed, or otherwise used, for any other purpose or by any other person without the written permission of the General Partner. It should be used by sophisticated investors who are knowledgeable of the risks involved. Past performance is not a guarantee of future results. Please refer to the relevant confidential offering document for full details on investment products and strategies of the Fund.

An investment in the Fund is subject to a high degree of investment risk, including the possible loss of the entire amount of such an investment. An investor should carefully read and review the confidential offering document, including the description of risk factors, before making an investment in the Fund.

The information contained herein reflects the current expectations, opinions, estimates and projections of the General Partner as of the date of publication, which are subject to change without notice at any time subsequent to the date of issue. The General Partner does not represent that any expectation, opinion, estimate or projection will be realized. All information provided is for informational purposes only and should not be deemed as investment advice or a recommendation to purchase or sell any specific security. While the information presented herein is believed to be reliable, no representation or warranty is made concerning the accuracy of any data presented. Prospective investors should not treat these materials as advice in relation to legal, taxation, or investment matters.

Statements herein that reflect projections or expectations of future financial or economic performance of the Fund are forward-looking statements. Such “forward-looking” statements are based on various assumptions, which assumptions may not prove to be correct. Accordingly, there can be no assurance that such assumptions and statements will accurately predict future events or the Fund’s actual performance. No representation or warranty can be given that the estimates,

opinions or assumptions made herein will prove to be accurate. Any projections and forward-looking statements included herein should be considered speculative and are qualified in their entirety by the information and risks disclosed in the confidential offering document. Actual results for any period may or may not approximate such forward-looking statements. Prospective investors are advised to consult with their own independent tax and business advisors concerning the validity and reasonableness of the factual, accounting and tax assumptions. No representations or warranties whatsoever are made by the Fund, the General Partner, any Fund affiliate, or any other person or entity as to the future profitability of the Fund or the results of making an investment in the Fund. Projected or past performance is not a guarantee of future results.

It is not anticipated that interests in the Fund will be registered under the securities laws or laws of similar import of any country or jurisdictions, including without limitation, the U.S. Securities Act of 1933, as amended (the “Securities Act”), nor qualified, approved or disapproved under any other U.S. or other securities laws. No regulatory authority of any jurisdiction has passed on or endorsed the merits of the Fund or interests therein. Any

representation to the contrary is unlawful. Interests in the Fund may not be sold, transferred or otherwise disposed of unless they are registered where required, including under the Securities Act, unless such interests and/or the proposed sale, transfer or disposition thereof is exempt from such registration. In addition, interests in the Fund may not be offered for sale, pledged, hypothecated, sold, assigned or transferred except in compliance with the terms of the limited partnership agreement of the Fund.

By accepting this information, the recipient agrees that it will not divulge any information contained herein to any other party. This presentation and its contents are confidential and proprietary information of the Fund and any reproduction of this information, in whole or in part, without the prior written consent of the General Partner is prohibited. Additional information is available from the General Partner upon request. The Fund, the General Partner, and their respective affiliates are not acting as your adviser or agent.

24